CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Nurix says Sanofi discontinues autoimmune disease drug program

By Reuters News

Nov 3 (Reuters) - Nurix Therapeutics NRIX.O said on Tuesday that Sanofi has decided to discontinue development of an experimental treatment for autoimmune and inflammatory diseases, eliminating potential future milestone payments and royalties related to the program.

Shares of Nurix plunged 38% in extended trading.

Here are more details:

  • The US biotech company said Sanofi SASY.PA had notified it of its decision to stop the development of SAR448272, an oral drug candidate, after discontinuing an early-stage trial

  • As a result, Nurix said it does not expect to receive any future development, regulatory or commercial milestone payments, or royalties associated with the treatment

  • Sanofi did not immediately respond to Reuters' request for comment

  • Nurix added that it remains eligible for milestone payments and royalties from other drug candidates being developed under its collaboration agreement with Sanofi

  • "While today's news is disappointing, Nurix remains in a strong position," CEO Arthur Sands said in a statement, citing the company's clinical-stage and preclinical pipeline

  • Nurix said it had cash, cash equivalents and marketable securities of about $1.1 billion as of August 31, which it expects to fund operations into the second half of 2029

  • Under a collaboration signed in 2019, Nurix used its targeted protein degradation platform to discover drug candidates for Sanofi

  • In 2025, Sanofi expanded the partnership by licensing two programs that target transcription factors for autoimmune and inflammatory diseases, including the now-discontinued candidate, Nurix said

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.